Defined serum-free media for in vitro expansion of adipose-derived mesenchymal stem cells

Cytotherapy

Volumn 16, Issue 7, 2014, Pages 915-926

  Al Saqi, Shahla Hamza ^a   Saliem, Mohammed ^a   Asikainen, Suvi ^a   Quezada, Hernan Concha ^b   Ekblad, Åsa ^a   Hovatta, Outi ^a   Le Blanc, Katarina ^a   Jonasson, Aino Fianu ^a   Götherström, Cecilia ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adipose derived mesenchymal stem cells; Bone marrow derived mesenchymal stem cells; Clinical cell culture; Mesenchymal stromal cells; Mesencult XF; Serum free medium

Indexed keywords

ADIPOSE DERIVED MESENCHYMAL STEM CELL; ADOLESCENT; ADULT; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL DIFFERENTIATION; CELL GROWTH; CELL ISOLATION; CELL LINEAGE; CELL STRUCTURE; CELL VIABILITY; CHILD; CONTROLLED STUDY; CULTURE MEDIUM; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTERMETHOD COMPARISON; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL CULTURE; STEM CELL EXPANSION; ADIPOSE TISSUE; BIOLOGICAL THERAPY; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; MESENCHYMAL STROMA CELL; PHARMACOLOGY;

BOVINAE;

CULTURE MEDIUM;

ADIPOSE TISSUE; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; CULTURE MEDIA, SERUM-FREE; HUMANS; MESENCHYMAL STROMAL CELLS;

EID: 84901975297     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.02.006     Document Type: Article

References (48)

1. Friedenstein A.J., Chailakhyan R.K., Latsinik N.V., Panasyuk A.F., Keiliss-Borok I.V. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues: cloning in vitro and retransplantation in vivo. Transplantation 1974, 17:331-340.
2. Kode J.A., Mukherjee S., Joglekar M.V., Hardikar A.A. Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy 2009, 11:377-391.
3. Porada C.D., Zanjani E.D., Almeida-Porad G. Adult mesenchymal stem cells: a pluripotent population with multiple applications. Curr Stem Cell Res Ther 2006, 1:365-369.
4. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells: the International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
5. Ortiz L.A., Gambelli F., McBride C., Gaupp D., Baddoo M., Kaminski N., et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003, 100:8407-8411.
6. Reinders M.E., Fibbe W.E., Rabelink T.J. Multipotent mesenchymal stromal cell therapy in renal disease and kidney transplantation. Nephrol Dial Transplant 2010, 25:17-24.
7. Wise A.F., Ricardo S.D. Mesenchymal stem cells in kidney inflammation and repair. Nephrology 2012, 17:1-10.
8. Hayes M., Curley G., Ansari B., Laffey J.G. Clinical review: stem cell therapies for acute lung injury/acute respiratory distress syndrome: hope or hype?. Crit Care 2012, 16:205.
9. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
10. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003, 57:11-20.
11. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
12. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002, 30:42-48.
13. Beitnes J.O., Oie E., Shahdadfar A., Karlsen T., Muller R.M., Aakhus S., et al. Intramyocardial injections of human mesenchymal stem cells following acute myocardial infarction modulate scar formation and improve left ventricular function. Cell Transplant 2012, 21(8):1697-1709.
14. Sensebe L., Bourin P. Mesenchymal stem cells for therapeutic purposes. Transplantation 2009, 87(Suppl 9):S49-S53.
15. Sundin M., Ringden O., Sundberg B., Nava S., Gotherstrom C., Le Blanc K. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 2007, 92:1208-1215.
16. Horwitz E.M., Gordon P.L., Koo W.K., Marx J.C., Neel M.D., McNall R.Y., et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002, 99:8932-8937.
17. Spees J.L., Gregory C.A., Singh H., Tucker H.A., Peister A., Lynch P.J., et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 2004, 9:747-756.
18. Stute N., Holtz K., Bubenheim M., Lange C., Blake F., Zander A.R. Autologous serum for isolation and expansion of human mesenchymal stem cells for clinical use. Exp Hematol 2004, 32:1212-1225.
19. Schallmoser K., Bartmann C., Rohde E., Reinisch A., Kashofer K., Stadelmeyer E., et al. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 2007, 47:1436-1446.
20. Zuk P.A., Zhu M., Mizuno H., Huang J., Futrell J.W., Katz A.J., et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001, 7:211-228.
21. Gimble J.M., Katz A.J., Bunnell B.A. Adipose-derived stem cells for regenerative medicine. Circ Res 2007, 100:1249-1260.
22. Connolly J.F., Guse R., Tiedeman J., Dehne R. Autologous marrow injection as a substitute for operative grafting of tibial nonunions. Clin Orthop Rel Res 1991, 266:259-270.
23. Mesimaki K., Lindroos B., Tornwall J., Mauno J., Lindqvist C., Kontio R., et al. Novel maxillary reconstruction with ectopic bone formation by GMP adipose stem cells. Int J Oral and Maxillofac Surg 2009, 38:201-209.
24. Kinnaird T., Stabile E., Burnett M.S., Lee C.W., Barr S., Fuchs S., et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004, 94:678-685.
25. Dharmasaroja P. Bone marrow-derived mesenchymal stem cells for the treatment of ischemic stroke. JClin Neurosci 2009, 16:12-20.
26. Lee J.W., Fang X., Krasnodembskaya A., Howard J.P., Matthay M.A. Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells 2011, 29:913-919.
27. Lane F.L., Jacobs S. Stem cells in gynecology. Am J Obstet Gynecol 2012, 207(3):149-156.
28. Carr L.K., Steele D., Steele S., Wagner D., Pruchnic R., Jankowski R., et al. One-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2008, 19:881-883.
29. Lee C.N., Jang J.B., Kim J.Y., Koh C., Baek J.Y., Lee K.J. Human cord blood stem cell therapy for treatment of stress urinary incontinence. JKorean Med Sci 2010, 25:813-816.
30. Witkowska-Zimny M., Walenko K. Stem cells from adipose tissue. Cell Mol Biol Lett 2011, 16:236-257.
31. Basu J., Genheimer C.W., Guthrie K.I., Sangha N., Quinlan S.F., Bruce A.T., et al. Expansion of the human adipose-derived stromal vascular cell fraction yields a population of smooth muscle-like cells with markedly distinct phenotypic and functional properties relative to mesenchymal stem cells. Tissue Eng Part C Methods 2011, 17:843-860.
32. Dicker A., Le Blanc K., Astrom G., van Harmelen V., Gotherstrom C., Blomqvist L., et al. Functional studies of mesenchymal stem cells derived from adult human adipose tissue. Exp Cell Res 2005, 308:283-290.
33. Strem B.M., Hicok K.C., Zhu M., Wulur I., Alfonso Z., Schreiber R.E., et al. Multipotential differentiation of adipose tissue-derived stem cells. Keio J Med 2005, 54:132-141.
34. Casteilla L., Planat-Benard V., Laharrague P., Cousin B. Adipose-derived stromal cells: their identity and uses in clinical trials, an update. World J Stem Cells 2011, 3:25-33.
35. Ikegame Y., Yamashita K., Hayashi S., Mizuno H., Tawada M., You F., et al. Comparison of mesenchymal stem cells from adipose tissue and bone marrow for ischemic stroke therapy. Cytotherapy 2011, 13:675-685.
36. Halvorsen Y.D., Bond A., Sen A., Franklin D.M., Lea-Currie Y.R., Sujkowski D., et al. Thiazolidinediones and glucocorticoids synergistically induce differentiation of human adipose tissue stromal cells: biochemical, cellular, and molecular analysis. Metabolism 2001, 50:407-413.
37. Kreshuk A., Straehle C.N., Sommer C., Koethe U., Cantoni M., Knott G., et al. Automated detection and segmentation of synaptic contacts in nearly isotropic serial electron microscopy images. PloS One 2011, 6:e24899.
38. Carpenter A.E., Jones T.R., Lamprecht M.R., Clarke C., Kang I.H., Friman O., et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 2006, 7:R100.
39. Kamentsky L., Jones T.R., Fraser A., Bray M.A., Logan D.J., Madden K.L., et al. Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software. Bioinformatics 2011, 27:1179-1180.
40. Bray L.J., Heazlewood C.F., Atkinson K., Hutmacher D.W., Harkin D.G. Evaluation of methods for cultivating limbalmesenchymal stromal cells. Cytotherapy 2012, 14(8):936-947.
41. Pal R., Hanwate M., Jan M., Totey S. Phenotypic and functional comparison of optimum culture conditions for upscaling of bone marrow-derived mesenchymal stem cells. JTissue Eng Regen Med 2009, 3:163-174.
42. Baglioni S., Francalanci M., Squecco R., Lombardi A., Cantini G., Angeli R., et al. Characterization of human adult stem-cell populations isolated from visceral and subcutaneous adipose tissue. FASEB J 2009, 23:3494-3505.
43. Schugar R.C., Chirieleison S.M., Wescoe K.E., Schmidt B.T., Askew Y., Nance J.J., et al. High harvest yield, high expansion, and phenotype stability of CD146 mesenchymal stromal cells from whole primitive human umbilical cord tissue. JBiomed Biotechnol 2009, 2009:789526.
44. Katz A.J., Mericli A.F. Stem Cells Derived from Fat 2011, Academic Press, London/Burlington/San Diego. 2nd edition. A. Atala, R. Lanza, J.A. Thomson, R.M. Nerem (Eds.).
45. Khan W.S., Adesida A.B., Tew S.R., Longo U.G., Hardingham T.E. Fat pad-derived mesenchymal stem cells as a potential source for cell-based adipose tissue repair strategies. Cell Prolif 2012, 45:111-120.
46. Campioni D., Lanza F., Moretti S., Ferrari L., Cuneo A. Loss of Thy-1 (CD90) antigen expression on mesenchymal stromal cells from hematologic malignancies is induced by in vitroangiogenic stimuli and is associated with peculiar functional and phenotypic characteristics. Cytotherapy 2008, 10:69-82.
47. Kyllonen L., Haimi S., Mannerstrom B., Huhtala H., Rajala K.M., Skottman H., et al. Effects of different serum conditions on osteogenic differentiation of human adipose stem cells in vitro. Stem cell Res Ther 2013, 4:17.
48. Choudhery M.S., Badowski M., Muise A., Pierce J., Harris D.T. Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation. JTransl Med 2014, 12:8.